Skip to main content

Branded

  • FDA review of MS drug extended, EMD Serono says

    ROCKLAND, Mass. — The Food and Drug Administration has extended its review period for a multiple sclerosis drug made by EMD Serono, the drug maker said Friday.

    EMD Serono — the U.S. subsidiary of German drug maker Merck KGaA, which uses the name to avoid confusion with U.S.-based Merck — said the FDA had extended the review time for cladribine tablets to Feb. 28. The drug is a disease-modifying drug for relapsing MS.

  • Antiviral drugs could cause insulin resistance, study finds

    ST. LOUIS — Since the beginning of the HIV/AIDS epidemic in the early 1980s, one of the greatest advances has been antiviral drugs that have helped extend the lives of patients with viral infections.

  • Study: Depression may be both a risk factor and consequence of diabetes

    NEW YORK — A new study published in the Nov. 22 issue of Archives of Internal Medicine suggested there is a two-way relationship between depression and diabetes.

  • FDA approves Axiron

    INDIANAPOLIS — Eli Lilly and Australian drug maker Acrux have received approval from the Food and Drug Administration for a testosterone replacement therapy for men, the two companies announced Tuesday.

    The FDA approved Axiron (testosterone) topical solution as a treatment for men with various conditions that lead to deficiency of the hormone. The drug, a controlled substance, is designed for application under the arm.

  • UnitedHealthcare partners with Kroger, Safeway on $2 generic Part D plan

    MINNETONKA, Minn. — UnitedHealth Group will start a program next year that it said can reduce drug costs to as low as $2 per script, the company said Tuesday.

    The program, Pharmacy Saver, will be available to Medicare Part D members and is a collaboration with Kroger, Safeway and Prescription Solutions. The program will allow members to purchase some scripts for $2 for 30- and some 90-day supplies and applies to hundreds of prescription drugs, including 8-of-the-10 most commonly used by UnitedHealthcare Medicare plan members.

  • New drug from Gilead may prevent HIV infection, study finds

    NEW YORK A daily dose of an anti-retroviral pill appears to prevent HIV infection, according to results of a study conducted by University of California at San Francisco researchers, published in The New England Journal of Medicine on Tuesday.

  • Vytorin helps reduce cardiac events in chronic kidney disease patients

    DENVER A cholesterol-lowering drug made by Merck appears to reduce the risk of heart attacks, strokes and cardiac death in patients with chronic kidney disease, according to results of a new study.

     

    Merck said results of a 9,000-patient clinical study showed that Vytorin (ezetimibe and simvastatin) reduced the risks by 16.1% compared with placebo. Results of the study were presented Saturday at the annual meeting of the American Society of Nephrology.

     

     

  • FDA asks Xanodyne to pull painkillers from market

    SILVER SPRING, Md. A drug maker will pull a common prescription painkiller from the market following the release of clinical data that it could cause heart problems.

     

X
This ad will auto-close in 10 seconds